Article

Association of EPHA3 mutations with tumor mutational burden and efficacy of immune checkpoint inhibitors in cancer patients

2022-02-09

Abstract excerpt

<h4>Background: </h4> The erythropoietin-producing human hepatocellular receptor A3 (EPHA3 ), which was identified as a tumor antigen targeted by a lytic T-cell response in melanoma patients, is relatively tumor specific. Moreover, EPHA3 is frequently mutated in human cancers, and the association of EPHA3 mutations with immunotherapy efficacy in cancer patients has not been reported to date. <h4>Methods:</h4> We c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1245321b-2489-512a-ba3b-bbe2ba0e979b
DOI: 10.21203/rs.3.rs-1308057/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Association of EPHA3 mutations with tumor mutational burden and efficacy of immune checkpoint inhibitors in cancer patientsDOI 10.21203/rs.3.rs-1308057/v1Read

EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.Semantic proximity Read

Systematic Pan-Cancer Analysis Reveals the Prognostic Value and Immunological Role of EPHX2Semantic proximity Read

The role of EPHA3 mutation in the prognosis of non-small cell lung cancer patients receiving immunotherapySemantic proximity Read

Comprehensive analysis of EphA2 in pan-cancer: A prognostic biomarker associated with cancer immunity.Semantic proximity Read

Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms.Semantic proximity Read

A comprehensive prognostic and immunological analysis of ephrin family genes in hepatocellular carcinomaSemantic proximity Read

EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma.Semantic proximity Read

The EPH/Ephrin System in Gynecological Cancers: Focusing on the Roots of Carcinogenesis for Better Patient ManagementSemantic proximity Read

Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinomaSemantic proximity Read

HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.Semantic proximity Read

High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.Semantic proximity Read

Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).Semantic proximity Read